Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hansa Biopharma AB (publ) (HNSA.ST)
SEK33.08
+0.34 (+1.04%)
SE STO Healthcare Biotechnology
Address
PO Box 785 220 07
Lund, SN, SE
Lund, SN, SE
CEO
Renee Aguiar-Lucander
Website
hansabiopharma.com
IPO
2007-10-17
ISIN SE0002148817
Also trades on
London Stock Exchange · 0RC7.L (SEK)
Other OTC · HNSBF (USD)
Stockholm Stock Exchange · HNSA.ST (SEK)
Description
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK33.08
+0.34 (+1.04%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
443.7K
Beta
1.59
Float Shares
62.70M
Free Float %
77.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.66% | +0.78% | +23.90% | -0.30% | -0.12% | +3.06% | +45.38% | -28.78% | -75.57% | -40.35% | +301.42% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
33.08
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.36
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+29.7% ★ Q1'26: -47.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+49.2% ★ Q1'26: -250.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-255.0% Q1'26: -454.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-184.2% Q1'26: -411.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-275.5% Q1'26: -298.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+29.2% Q1'26: +50.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.28× Q1'26: -2.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 6 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.43M
est: 6.08M (-10.7%)
|
2.58M
est: 3.00M (-14.0%)
|
3.44M
est: 3.06M (+12.3%)
|
3.36M
est: 3.33M (+0.7%)
|
3.36M
est: 3.39M (-0.8%)
|
6.10M
est: 22.76M (-73.2%)
|
33.88M
est: 31.99M (+5.9%)
|
154.53M
est: 128.12M (+20.6%)
|
134.09M
est: 163.56M (-18.0%)
|
171.32M
est: 199.78M (-14.2%)
|
222.27M
est: 203.99M (+9.0%)
|
257.43M
82.40M – 445.04M
+26.2% YoY
|
501.08M
184.45M – 1.03B
+94.6% YoY
|
980.86M
966.32M – 995.41M
+95.7% YoY
|
2.12B
718.24M – 3.94B
+115.7% YoY
|
3.16B
1.07B – 5.88B
+49.2% YoY
|
| EBITDA |
-65.21M
est: -6.08M (-972.1%)
|
-107.60M
est: -3.00M (-3,486.8%)
|
-172.30M
est: -3.06M (-5,523.9%)
|
-245.47M
est: -3.33M (-7,264.1%)
|
-352.21M
est: -3.39M (-10,283.7%)
|
-413.08M
est: -22.76M (-1,714.9%)
|
-538.83M
est: -31.99M (-1,584.3%)
|
-554.26M
est: -128.12M (-332.6%)
|
-714.55M
est: -163.56M (-336.9%)
|
-642.07M
est: -199.78M (-221.4%)
|
-409.35M
est: -203.99M (-100.7%)
|
-257.43M
-445.04M – -82.40M
-26.2% YoY
|
-501.08M
-1.03B – -184.45M
-94.6% YoY
|
-980.86M
-995.41M – -966.32M
-95.7% YoY
|
-2.12B
-3.94B – -718.24M
-115.7% YoY
|
-3.16B
-5.88B – -1.07B
-49.2% YoY
|
| EBIT |
-66.20M
est: -6.08M (-988.4%)
|
-111.05M
est: -3.00M (-3,601.6%)
|
-176.00M
est: -3.06M (-5,644.6%)
|
-247.31M
est: -3.33M (-7,319.2%)
|
-359.13M
est: -3.39M (-10,487.4%)
|
-420.64M
est: -22.76M (-1,748.1%)
|
-547.44M
est: -31.99M (-1,611.2%)
|
-566.31M
est: -128.12M (-342.0%)
|
-725.29M
est: -163.56M (-343.4%)
|
-670.13M
est: -199.78M (-235.4%)
|
-409.35M
est: -203.99M (-100.7%)
|
-257.43M
-445.04M – -82.40M
-26.2% YoY
|
-501.08M
-1.03B – -184.45M
-94.6% YoY
|
-980.86M
-995.41M – -966.32M
-95.7% YoY
|
-2.12B
-3.94B – -718.24M
-115.7% YoY
|
-3.16B
-5.88B – -1.07B
-49.2% YoY
|
| Net Income |
-66.27M
est: -124.84M (+46.9%)
|
-111.13M
est: -232.49M (+52.2%)
|
-176.66M
est: -281.05M (+37.1%)
|
-247.97M
est: -320.14M (+22.5%)
|
-360.01M
est: -548.08M (+34.3%)
|
-420.85M
est: -591.04M (+28.8%)
|
-548.28M
est: -733.75M (+25.3%)
|
-611.13M
est: -805.92M (+24.2%)
|
-831.72M
est: -801.64M (-3.8%)
|
-807.24M
est: -596.68M (-35.3%)
|
-529.25M
est: -691.58M (+23.5%)
|
-43.52M
-60.51M – 76.42M
+93.7% YoY
|
-527.00M
-633.40M – -226.21M
-1,111.0% YoY
|
-315.11M
-386.98M – 8.02M
+40.2% YoY
|
327.24M
46.22M – 694.08M
+203.8% YoY
|
1.03B
144.90M – 2.18B
+213.5% YoY
|
| SGA |
28.24M
est: 61.44M (-54.0%)
|
29.70M
est: 30.30M (-2.0%)
|
43.72M
est: 30.95M (+41.3%)
|
90.39M
est: 33.67M (+168.5%)
|
167.31M
est: 34.26M (+388.3%)
|
202.99M
est: 229.89M (-11.7%)
|
327.27M
est: 323.13M (+1.3%)
|
337.86M
est: 1.29B (-73.9%)
|
450.49M
est: 615.65M (-26.8%)
|
344.27M
est: 751.97M (-54.2%)
|
356.55M
est: 767.83M (-53.6%)
|
968.95M
310.16M – 1.68B
+26.2% YoY
|
1.89B
694.25M – 3.89B
+94.6% YoY
|
3.69B
3.64B – 3.75B
+95.7% YoY
|
7.97B
2.70B – 14.83B
+115.7% YoY
|
11.89B
4.03B – 22.14B
+49.2% YoY
|
| EPS |
-2.12
est: -1.99 (-6.7%)
|
-3.37
est: -3.70 (+8.9%)
|
-4.97
est: -4.47 (-11.1%)
|
-6.47
est: -5.10 (-27.0%)
|
-9.00
est: -8.72 (-3.2%)
|
-9.98
est: -9.41 (-6.1%)
|
-12.33
est: -11.68 (-5.6%)
|
-13.60
est: -12.83 (-6.0%)
|
-15.83
est: -14.52 (-9.0%)
|
-12.84
est: -10.40 (-23.4%)
|
-6.52
est: -5.99 (-8.8%)
|
-0.37
-0.75 – 0.94
+93.8% YoY
|
-4.92
-7.80 – -2.79
-1,219.7% YoY
|
-1.97
-4.77 – 0.10
+60.0% YoY
|
4.03
0.57 – 8.55
+304.8% YoY
|
12.64
1.78 – 26.80
+213.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-533.90M
OE per share TTM
-5.90
Owner's Yield
-15.57%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
22.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 3 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.01% | 130.1K | 0.40% |
| 2 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 599.9K | 0.03% |
| 3 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 5.1K | 0.07% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-2.97M
Shares Outstanding
81.21M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Renee Aguiar-Lucander | Chief Executive Officer | 11M | female |
| C. Evan Ballantyne | Chief Financial Officer | — | male |
| Emanuel Björne | Vice President & Head of Business Development | — | male |
| Eva-Maria Joed | Vice President of Finance & Administration | — | female |
| Hitto Kaufmann | Chief Scientific & Technology Officer | — | — |
| Klaus Sindahl | Vice President & Head of Investor Relations | — | male |
| Lena Winstedt | Head of Science | — | — |
| Monika Tornsen | Chief Operating Officer & President of U.S. | — | female |
| Sandra Frithiof | Chief Human Resources Officer | — | female |
| Brian Gorman | Chief Legal Officer and Corporate Secretary | — | male |
| Vincenza Nigro | Vice President & Head of Medical Affairs | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HNSA.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
